BIO Korea 2016: SillaJen On Maximizing Value Of Pexa-Vec

South Korea's SillaJen, which has ambitions to launch its oncolytic virus-based immunotherapy Pexa-Vec in global markets in the next few years, has unveiled progress of its global Phase III study and the company's global strategy during the recent BIO Korea 2016 in Seoul.

SEOUL - SillaJen Inc., which has just begun a global Phase III study of its oncolytic virus-based immunotherapy Pexa-Vec for hepatocellular carcinoma (HCC), aims to retain rights in some regions until as late as possible in order to maximize the value of the project.

Pexa-Vec (JX-594, pexastimogene devacirepvec) is the most advanced product candidate from the private South Korean clinical-stage biotherapeutics firm’s proprietary SOLVE...